Sulodexide

Oral
Diabetic neuropathy
Adult: 1-2 capsules (250-500 lipasemic units [LSU]; 10 LSU is equivalent to 1 mg) bid for 30-40 days. Generally, therapy starts with the inj for 15-20 days and then continued with the oral form. Repeat the treatment cycle at least twice yearly. Dosage quantity and frequency may vary according to the physician's evaluation.

Oral
Deep vein thrombosis
Adult: 1-2 capsules (250-500 lipasemic units [LSU]; 10 LSU is equivalent to 1 mg) bid for 30-40 days. Generally, therapy starts with the inj for 15-20 days and then continued with the oral form. Repeat the treatment cycle at least twice yearly. Dosage quantity and frequency may vary according to the physician's evaluation.

Oral
Myocardial infarction
Adult: 1-2 capsules (250-500 lipasemic units [LSU]; 10 LSU is equivalent to 1 mg) bid for 30-40 days. Generally, therapy starts with the inj for 15-20 days and then continued with the oral form. Repeat the treatment cycle at least twice yearly. Dosage quantity and frequency may vary according to the physician's evaluation.

Oral
Cerebrovascular disorders
Adult: 1-2 capsules (250-500 lipasemic units [LSU]; 10 LSU is equivalent to 1 mg) bid for 30-40 days. Generally, therapy starts with the inj for 15-20 days and then continued with the oral form. Repeat the treatment cycle at least twice yearly. Dosage quantity and frequency may vary according to the physician's evaluation.

Oral
Diabetic nephropathy
Adult: 1-2 capsules (250-500 lipasemic units [LSU]; 10 LSU is equivalent to 1 mg) bid for 30-40 days. Generally, therapy starts with the inj for 15-20 days and then continued with the oral form. Repeat the treatment cycle at least twice yearly. Dosage quantity and frequency may vary according to the physician's evaluation.

Oral
Peripheral arterial occlusive disease
Adult: 1-2 capsules (250-500 lipasemic units [LSU]; 10 LSU is equivalent to 1 mg) bid for 30-40 days. Generally, therapy starts with the inj for 15-20 days and then continued with the oral form. Repeat the treatment cycle at least twice yearly. Dosage quantity and frequency may vary according to the physician's evaluation.

Oral
Diabetic retinopathy
Adult: 1-2 capsules (250-500 lipasemic units [LSU]; 10 LSU is equivalent to 1 mg) bid for 30-40 days. Generally, therapy starts with the inj for 15-20 days and then continued with the oral form. Repeat the treatment cycle at least twice yearly. Dosage quantity and frequency may vary according to the physician's evaluation.

Oral
Transient ischaemic attack
Adult: 1-2 capsules (250-500 lipasemic units [LSU]; 10 LSU is equivalent to 1 mg) bid for 30-40 days. Generally, therapy starts with the inj for 15-20 days and then continued with the oral form. Repeat the treatment cycle at least twice yearly. Dosage quantity and frequency may vary according to the physician's evaluation.

Oral
Venous leg ulcer
Adult: 1-2 capsules (250-500 lipasemic units [LSU]; 10 LSU is equivalent to 1 mg) bid for 30-40 days. Generally, therapy starts with the inj for 15-20 days and then continued with the oral form. Repeat the treatment cycle at least twice yearly. Dosage quantity and frequency may vary according to the physician's evaluation.

Parenteral
Venous leg ulcer
Adult: 1 amp (600 LSU) via IM or IV inj daily for 15-20 days. Continue with the oral form for 30-40 days. Repeat the treatment cycle at least twice yearly. Dosage quantity and frequency may vary according to the physician's evaluation.

Parenteral
Transient ischaemic attack
Adult: 1 amp (600 LSU) via IM or IV inj daily for 15-20 days. Continue with the oral form for 30-40 days. Repeat the treatment cycle at least twice yearly. Dosage quantity and frequency may vary according to the physician's evaluation.

Parenteral
Diabetic retinopathy
Adult: 1 amp (600 LSU) via IM or IV inj daily for 15-20 days. Continue with the oral form for 30-40 days. Repeat the treatment cycle at least twice yearly. Dosage quantity and frequency may vary according to the physician's evaluation.

Parenteral
Peripheral arterial occlusive disease
Adult: 1 amp (600 LSU) via IM or IV inj daily for 15-20 days. Continue with the oral form for 30-40 days. Repeat the treatment cycle at least twice yearly. Dosage quantity and frequency may vary according to the physician's evaluation.

Parenteral
Diabetic nephropathy
Adult: 1 amp (600 LSU) via IM or IV inj daily for 15-20 days. Continue with the oral form for 30-40 days. Repeat the treatment cycle at least twice yearly. Dosage quantity and frequency may vary according to the physician's evaluation.

Parenteral
Cerebrovascular disorders
Adult: 1 amp (600 LSU) via IM or IV inj daily for 15-20 days. Continue with the oral form for 30-40 days. Repeat the treatment cycle at least twice yearly. Dosage quantity and frequency may vary according to the physician's evaluation.

Parenteral
Myocardial infarction
Adult: 1 amp (600 LSU) via IM or IV inj daily for 15-20 days. Continue with the oral form for 30-40 days. Repeat the treatment cycle at least twice yearly. Dosage quantity and frequency may vary according to the physician's evaluation.

Parenteral
Deep vein thrombosis
Adult: 1 amp (600 LSU) via IM or IV inj daily for 15-20 days. Continue with the oral form for 30-40 days. Repeat the treatment cycle at least twice yearly. Dosage quantity and frequency may vary according to the physician's evaluation.

Parenteral
Diabetic neuropathy
Adult: 1 amp (600 LSU) via IM or IV inj daily for 15-20 days. Continue with the oral form for 30-40 days. Repeat the treatment cycle at least twice yearly. Dosage quantity and frequency may vary according to the physician's evaluation.

Should be taken on an empty stomach (i.e. At least one hour before food or two hours after food).

Hypersensitivity to heparin and heparinoids. Haemorrhagic disease or diathesis. Pregnancy.

Monitoring Parameters Monitor haemocoagulative parameters periodically.

Gastrointestinal disorders: Diarrhoea, nausea, vomiting, epigastralgia. General disorders and administration site conditions: Burning sensation, pain, and haematoma at inj site.

May increase the anticoagulation effects of heparin and oral anticoagulants.

Sulodexide is a sulfated polysaccharide complex consisting of 80% low molecular weight heparin and 20% dermatan sulfate. It exerts its antithrombotic activity through dose-dependent inhibition of activated coagulation factor X, as well as inhibition of platelet aggregation and activation of the circulating and parietal fibrinolytic system. Sulodexide also normalises the viscosimetric parameters that are usually altered in patients with vascular pathologies with thrombotic risk, mainly by reducing fibrinogen levels.
Absorption: Rapidly absorbed. Bioavailability: 20-60%. Time to peak plasma concentration: 4 hours (oral).
Distribution: Widely distributed, particularly in the monocellular endothelial layer.
Metabolism: Metabolised in the liver.
Excretion: Mainly via urine (55.3 ± 2.9%); bile (23.5 ± 2.3%) and faeces (23.5 ± 2.8%). Elimination half-life: 18.7 ± 4. 1 hours (50 mg dose); 25.8 ± 1.9 hours (100 mg dose).

Oral: Store below 25°C. Parenteral: Store below 25°C.

Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)

B01AB11 - sulodexide ; Belongs to the class of heparin group. Used in the treatment of thrombosis.